Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORKiDs trial of primary cyclosporine A + IVIG + aspirin in Kawasaki disease
jRCTs031230101Recruiting
- Sponsor
- CREATION-Fund of CUH
- Start
- Jun 2023
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Open-label, single-arm trial of cyclosporine, immune globulin and aspirin in Kawasaki disease (KD), sponsored by CREATION-Fund of CUH. Primary endpoint: Presence or absence of coronary artery abnormalities through week 4. Started Jun 2023; status: recruiting.
02
Drugs
cyclosporineimmune globulinaspirin
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on jRCTs031230101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230101.